Biotechnology - UK

Filter

Current filters:

UK

Popular Filters

1 to 25 of 87 results

New $11 million Biotech Innovation Hub opens in Birmingham, UK

New $11 million Biotech Innovation Hub opens in Birmingham, UK

16-12-2014

A new biomedical laboratory, the Biomedical Innovation Hub (the BioHub) has opened in Birmingham, UK.

BiotechnologyBirminghamResearchUKUnited Kingdom

NetScientific invests in PDS Biotechnology

NetScientific invests in PDS Biotechnology

15-12-2014

UK-based life sciences investor NetScientific has made an undisclosed investment in privately-held US…

Antibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsNetScientificOncologyPDS BiotechnologyUK

Valneva and BliNK Therapeutics launch new biotech company

Valneva and BliNK Therapeutics launch new biotech company

12-12-2014

France-based biotech firm Valneva and privately-held UK company BliNK Therapeutics have created a private…

BiotechnologyBliNK BiomedicalBliNK TherapeuticsFinancialFranceMergers & AcquisitionsUKValneva

Celgene appoints Wim Souverijns as vice president general manager for UK and Ireland

Celgene appoints Wim Souverijns as vice president general manager for UK and Ireland

11-12-2014

US biotech company Celgene has appointed Wim Souverijns as vice president general manager for the UK…

BiotechnologyBoardroomCelgene Corp.UKUK & Ireland

NICE now proposes to recommend Stelara for psoriatic arthritis

NICE now proposes to recommend Stelara for psoriatic arthritis

09-12-2014

UK health cost watchdog, the National Institute for Health and Care Excellence (NICE) has opened a consultation…

Anti-Arthritics/RheumaticsBiotechnologyInflammatory diseasesJanssenJohnson & JohnsonPricingRegulationStelaraUK

Medical Research Council develops XNAzyme, a world-first synthetic enzyme

Medical Research Council develops XNAzyme, a world-first synthetic enzyme

01-12-2014

Scientists from the UK's Medical Research Council have created the world’s first artificial enzymes…

BiotechnologyChemistryGeneticsMedical Research CouncilResearchUK

NICE final draft guidance recommends Soliris, but saying it is “very expensive”

NICE final draft guidance recommends Soliris, but saying it is “very expensive”

27-11-2014

The UK National Institute for Health and Care Excellence (NICE) has today issued final draft guidance…

Alexion PharmaceuticalsBiotechnologyPricingRare diseasesRegulationSolirisUK

Modern Biosciences announces RA R&D agreement with Janssen Biotech

Modern Biosciences announces RA R&D agreement with Janssen Biotech

27-11-2014

UK-based drug development company Modern Biosciences has entered into an R&D alliance and global option…

Anti-Arthritics/RheumaticsBiotechnologyJanssen BiotechLicensingModern BiosciencesUK

Takeda's Entyvio given provisional approval by UK's NICE

Takeda's Entyvio given provisional approval by UK's NICE

26-11-2014

The UK’s National Institute for Health and Care Excellence (NICE) has given a provisional approval…

BiotechnologyEntyvioGastro-intestinalsRegulationTakeda PharmaceuticalUK

UK government looks to speed up access to new medicines

UK government looks to speed up access to new medicines

20-11-2014

The UK government has announced a substantial investment package from industry, and that it is to carry…

BiotechnologyPoliticsRegulationUKUnited Kingdom

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

04-11-2014

Anglo-Swedish drug major AstraZeneca and US health care giant Johnson & Johnson’s Europe-based subsidiary…

AstraZenecaBiotechnologyImbruvicaJanssenMEDI4736OncologyPharmacyclicsResearchUK

Licensing deal index shows re-emergence of late-stage deals

Licensing deal index shows re-emergence of late-stage deals

28-10-2014

Licensing deals among biotech companies have recently shown a healthy surge, especially in later stages.

BiotechnologyCelgene Corp.FinancialLicensingMorrisonUK

Amgen advised to consider ‘radical’ split by lead investor

Amgen advised to consider ‘radical’ split by lead investor

22-10-2014

One of Amgen’s largest shareholders has said the USA-based biotechnolgy comapny would be better off…

AmgenBiotechnologyFinancialThousand Oaks, CaliforniaUK

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

Dendreon’s Provenge too expensive to be recommended, says NICE in draft guidance

16-10-2014

In preliminary draft guidance issued this morning the UK health costs watchdog the National Institute…

BiotechnologyDendreonOncologyPricingProvengeRegulationUK

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

NICE preliminary guidance negative on Celgene’s pomalidomide for multiple myeloma

15-10-2014

UK medical costs watchdog the National Institute for Health and Care Excellence (NICE) has issued preliminary…

BiotechnologyCelgene Corp.ImnovidOncologyPricingRegulationUK

UK Bioscience Forum: Incentivize investors to hold their investment for more than 10 years

UK Bioscience Forum: Incentivize investors to hold their investment for more than 10 years

08-10-2014

One of the main messages from the keynote speech at the UK Bioscience Forum by Paul Drayson, chief executive…

BiotechnologyLegalLicensingPatents & Trade marksProductionRegulationResearchSocial IssuesUK

Yale's Stephen Waxman to collaborate with Convergence Pharmaceuticals on chronic pain

Yale's Stephen Waxman to collaborate with Convergence Pharmaceuticals on chronic pain

06-10-2014

Convergence Pharmaceuticals Holdings, focused on developing analgesic medicines, is to collaborate with…

AnalgesiaBiotechnologyConvergence PharmaceuticalsResearchUK

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

02-10-2014

UK biotech firm Oxford BioTherapeutics and family-owned Italian Berlin Chemie/Menarini Group have designated…

BiotechnologyItalyMenariniOncologyOxford BioTherapeuticsResearchUK

Avacta Life Sciences invests $16.2 million in Affimers as engineered alternative to antibodies

Avacta Life Sciences invests $16.2 million in Affimers as engineered alternative to antibodies

30-09-2014

Avacta Life Sciences, a division of Avacta Group is investing £10 million ($16.2 million) in the launch…

AvactaBiotechnologyResearchUK

AstraZeneca's Medimmune to collaborate on new oncology biologics lab with Cancer Research UK

AstraZeneca's Medimmune to collaborate on new oncology biologics lab with Cancer Research UK

25-09-2014

Medimmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

BiotechnologyCancer Research TechnologyCancer Research UKMedImmuneOncologyResearchUK

Adaptimmune completes $104 million round of financing to advance cancer therapies

Adaptimmune completes $104 million round of financing to advance cancer therapies

25-09-2014

Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease,…

AdaptimmuneBiotechnologyFinancialGlaxoSmithKlineOncologyUK

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

UK’s NICE recommends Celgene’s Revlimid for myelodysplastic syndromes

24-09-2014

The UK’s drug watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgene Corp.OncologyPricingRegulationRevlimidUK

1 to 25 of 87 results

Back to top